Real-life efficacy and toxicity of lutetium peptide receptor radionuclide therapy in patients with progressive, metastatic neuroendocrine tumors who failed at least one line of systemic treatment

#3868

Introduction: Peptide receptor radionuclide therapy using lutetium-177 (PRRT) is thought to be an effective treatment (tx) for patients (pts) with somatostatin-receptor–positive, advanced, progressive neuroendocrine tumors. Real-life experience data has been lacking.

Aim(s): To report a real-life single centre experience with PRRT, describing efficacy and safety.

Materials and methods: Descriptive statistics, Kaplan–Meier and Cox regression were used to analyse cohort clinicopathological data.

Conference:

Presenting Author:

Authors: Kavan P, Rho H, Probst S, Abikhzer G, Rho Y,

Keywords: neuroendocrine tumor, lutetium, PRRT, efficacy, safety,